arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Anavex Life Sciences Corp.

AVXL Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$1.31
▼ -3.3% Today
as of Oct 23, 15:30 ET
Last 30 days -49.42% Sep 14 → Oct 23
$1.14 $1.53 $1.92 $2.32 $2.71 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$1.33
High
$1.41
Low
$1.33
Volume
$1M
Avg Vol
$2M
Mkt Cap
$300M
P/E (TTM)
—
Beta
—
52w High
$9.40
52w Low
$1.14
Div Yield
—
Shares Out
$93M

Recent Press Releases & News last 60 days · 18 items

Oct 20 · 20:00 PR GlobeNewswire
Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
Oct 16 · 13:33 InvestorsHub
Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial
Oct 15 · 21:10 MT Newswires
Anavex Gets FDA Clearance to Study Blarcamesine in Fragile X Syndrome
▸ Show all 18 press releases & news Free account →

AVXL earnings at a glance

The options market is pricing a move of about ±45.8% after the report, a range of roughly $0.71 to $1.91 from today's $1.31. Over its last 1 reports the stock rose the next day 0 times and fell 1, moving ±5.0% on average; after the most recent report on May 13, 2025 it moved -5.0%. That means options currently expect more movement than AVXL has typically delivered. AVXL beat the consensus EPS estimate in 1 of its last 2 reported quarters. Implied volatility is currently 387%. The share price of $1.31 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.14
$9.40
2% of range
Avg surprise (last 2)
-2.2%
Avg reaction (last 1)
-5.0%
0% positive
Latest IV / EM
387%
EM ±45.8% · $2 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.17$-0.11$-0.05$0.02$0.08 Actual $-0.17Actual $-0.17Actual $-0.14Actual $-0.11Actual $-0.13Actual $-0.14Actual $-0.14Actual $-0.13Est $-0.16Actual $-0.16Est $-0.13Actual $-0.06Actual $-0.06Actual $0.08 DecMarJunDecMarJunDecMar/2025Jun/2025DecMarJun
Revenue vs Net Income Revenue Net income
$-13M$-8M$-3M$3M$8M Dec 24Mar 25Jun 25Dec 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $0.08 — — — — financials
Tue Mar 31, 2026Mar 2026 $-0.06 — — — — financials
Wed Dec 31, 2025Dec 2025 $-0.06 — — — — financials
Tue Aug 12, 2025Jun/2025 $-0.16 $-0.13 -23.1% — — earnings
Tue May 13, 2025Mar/2025 $-0.13 $-0.16 +18.8% — -5.0% earnings
Tue Dec 31, 2024Dec 2024 $-0.14 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.14 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.13 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.11 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.14 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.17 — — — — financials
Sat Dec 31, 2022Dec 2022 $-0.17 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$7M$-6M$-7M—$-14M$-13M$-14M—
Net income$8M$-5M$-6M—$-13M$-11M$-12M—
EPS (diluted)$0.08$-0.06$-0.06—$-0.16$-0.13$-0.14—

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$118M$127M$132M$103M$101M$116M$121M$132M
Inventory————————
Total current assets————————
Total assets$120M$129M$133M$104M$102M$117M$124M$136M
Long-term debt————————
Total liabilities$8M$7M$6M$9M$11M$17M$13M$15M
Total equity$112M$122M$127M$95M$91M$100M$111M$120M

Implied volatility — last 90 days

32%444%855%1266%1678% Jun 06 — IV 208% · EM ±38.0%Jun 07 — IV 162% · EM ±22.4%Jun 08 — IV 217% · EM ±28.6%Jun 09 — IV 314% · EM ±39.4%Jun 10 — IV 466% · EM ±55.1%Jun 11 — IV 385% · EM ±42.5%Jun 12 — IV 430% · EM ±44.0%Jun 16 — IV 672% · EM ±39.7%Jun 17 — IV 628% · EM ±26.2%Jun 19 — IV 108% · EM ±23.8%Jun 22 — IV 118% · EM ±24.6%Jun 23 — IV 109% · EM ±22.3%Jun 24 — IV 122% · EM ±24.4%Jun 25 — IV 300% · EM ±58.8%Jun 26 — IV 115% · EM ±21.9%Jun 29 — IV 114% · EM ±20.2%Jun 30 — IV 118% · EM ±20.3%Jul 01 — IV 197% · EM ±32.9%Jul 02 — IV 92% · EM ±14.9%Jul 03 — IV 99% · EM ±15.4%Jul 06 — IV 115% · EM ±16.0%Jul 07 — IV 126% · EM ±16.6%Jul 08 — IV 192% · EM ±24.1%Jul 09 — IV 188% · EM ±22.2%Jul 10 — IV 872% · EM ±96.3%Jul 13 — IV 382% · EM ±31.9%Jul 14 — IV 427% · EM ±30.9%Jul 15 — IV 610% · EM ±36.0%Jul 20 — IV 101% · EM ±23.8%Jul 21 — IV 194% · EM ±45.1%Jul 22 — IV 150% · EM ±34.3%Jul 23 — IV 247% · EM ±55.6%Jul 27 — IV 182% · EM ±38.0%Jul 28 — IV 143% · EM ±29.2%Jul 29 — IV 541% · EM ±108.4%Jul 30 — IV 246% · EM ±48.1%Jul 31 — IV 104% · EM ±20.0%Aug 03 — IV 91% · EM ±16.1%Aug 04 — IV 92% · EM ±15.9%Aug 05 — IV 75% · EM ±12.5%Aug 06 — IV 94% · EM ±15.2%Aug 07 — IV 105% · EM ±16.5%Aug 10 — IV 117% · EM ±16.2%Aug 11 — IV 241% · EM ±31.8%Aug 12 — IV 152% · EM ±19.1%Aug 13 — IV 220% · EM ±26.0%Aug 14 — IV 98% · EM ±10.8%Aug 17 — IV 121% · EM ±10.1%Aug 18 — IV 130% · EM ±9.4%Aug 19 — IV 325% · EM ±19.2%Aug 20 — IV 268% · EM ±11.2%Aug 24 — IV 131% · EM ±27.3%Aug 25 — IV 100% · EM ±20.5%Aug 26 — IV 81% · EM ±16.2%Aug 27 — IV 33% · EM ±6.4%Aug 28 — IV 52% · EM ±10.0%Aug 31 — IV 81% · EM ±14.4%Sep 01 — IV 91% · EM ±15.7%Sep 02 — IV 51% · EM ±8.6%Sep 03 — IV 130% · EM ±21.1%Sep 04 — IV 112% · EM ±17.5%Sep 07 — IV 126% · EM ±17.5%Sep 08 — IV 86% · EM ±11.4%Sep 09 — IV 138% · EM ±17.3%Sep 10 — IV 175% · EM ±20.7%Sep 11 — IV 189% · EM ±20.8%Sep 14 — IV 898% · EM ±75.0%Sep 15 — IV 1678% · EM ±121.4%Sep 17 — IV 944% · EM ±39.4%Sep 21 — IV 200% · EM ±41.7%Sep 22 — IV 188% · EM ±38.5%Sep 23 — IV 223% · EM ±44.7%Sep 24 — IV 196% · EM ±38.5%Sep 28 — IV 240% · EM ±42.6%Sep 29 — IV 209% · EM ±36.0%Sep 30 — IV 216% · EM ±36.0%Oct 01 — IV 99% · EM ±16.0%Oct 06 — IV 426% · EM ±56.2%Oct 08 — IV 387% · EM ±45.8%

Sector peers

SRZN
Surrozen, Inc.
$296M $25.61+1.2%
IPSC
Century Therapeutics, Inc.
$292M $1.47-9.0%
CABA
Cabaletta Bio, Inc.
$320M $1.46-5.2%
XFOR
X4 Pharmaceuticals, Inc.
$279M $3.23+7.1%
SABS
SAB Biotherapeutics, Inc.
$278M $2.88+2.1%
FATE
Fate Therapeutics, Inc.
$276M $2.10+1.4%

AVXL earnings FAQ

What is AVXL's expected move for earnings?

Options currently price a move of about ±45.8%, or $0.60 per share either way from $1.31.

How does AVXL stock usually react to earnings?

Across the last 1 reports the average next-day move was ±5.0%, up 0 times and down 1 times.

What is AVXL's implied volatility?

AVXL's at-the-money implied volatility is about 387% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in